Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Management of Dyslipidemia in Adult Type 2 Diabetes Patients in India (SOLID)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT01292018
First received: January 31, 2011
Last updated: February 20, 2013
Last verified: February 2013

January 31, 2011
February 20, 2013
February 2011
Not Provided
Proportion of type 2 diabetic dyslipidemia patients achieving the target LDL goal according to ADA 2010. These patients should be on stable dose of Lipid Lowering Drugs(LDL) for at least 3 months [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01292018 on ClinicalTrials.gov Archive Site
  • Proportion of dyslipidemia control rate according to american diabetes Association (ADA) 2010 criteria by age and gender [ Designated as safety issue: No ]
  • Control of dyslipidemia by Lipid Lowering Drugs (LLDs) drugs alone or combination [ Designated as safety issue: No ]
  • Control of dyslipidemia by all commercial available brands hypolipidemics drugs [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Management of Dyslipidemia in Adult Type 2 Diabetes Patients in India
A Non Interventional, Cross Sectional, Epidemiological Study on the Management of Dyslipidemia in Type 2 DM Adult Patients in India

The purpose of study to assess the control of dyslipidemia in the Indian diabetic population treated with any hypolipidemic agent.

Not Provided
Observational
Observational Model: Cohort
Time Perspective: Cross-Sectional
Not Provided
Retention:   Samples Without DNA
Description:

Lipid profile ( Low Density Lipoproteins(LDL), High Density Lipoprotein (HDL), Triglycerides & Total cholesterol) Blood Glucose Measurements (Fasting Plasma Glucose)

Non-Probability Sample

Type 2 Diabetics with dyslipidemia on stable dose of Lipid Lowering Drugs(LLDs).

  • Dyslipidemia
  • Type 2 Diabetes Mellitus
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
5400
February 2012
Not Provided

Inclusion Criteria:

  • Adult who is a known Type 2 diabetic as per the ADA 2010 criteria OR controlled diabetic (taking any antidiabetic medication)
  • Patients in the study will have been on lipid lowering drugs at a stable dose for the last three months before the designated study visit.

Exclusion Criteria:

  • Type 1 diabetic patients
  • Patients with a history of hepatic or renal diseases
  • Hypertension due to organic diseases
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT01292018
NIS-CIN-DUM-2010/1
No
AstraZeneca
AstraZeneca
Not Provided
Not Provided
AstraZeneca
February 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP